Business Context and Reporting Period
Company: Personalis, Inc. (PSNL)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2024
Business Overview: Personalis develops and markets advanced cancer genomic tests and analytics for precision oncology. Its primary customers include pharmaceutical companies for clinical trials, biopharmaceutical companies, and government entities (e.g., VA Million Veteran Program). The company is expanding into the clinical diagnostics market via a commercialization agreement with Tempus AI, Inc.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $22,580 | $16,699 | $42,105 | $35,559 |
| Net Loss | $(12,802) | $(23,955) | $(25,770) | $(52,614) |
| Loss Per Share (Basic/Diluted) | $(0.24) | $(0.50) | $(0.50) | $(1.11) |
| Operating Cash Flow | — | — | $(31,156) | $(26,159) |
| Cash & Short-Term Investments | $86,972 | — | $86,972 | — |
| Total Debt | $2,281 | — | $2,281 | — |
Note: Q2 2023 Operating Cash Flow is not explicitly provided in the text, but YTD figures are available.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35% in Q2 2024 compared to Q2 2023, driven primarily by a 117% increase in "Pharma tests and services" revenue ($13.2M vs. $6.1M). This was partially offset by a 57% decline in "Population sequencing" revenue due to lower sample volumes from the VA MVP.
- Expense Reduction: Research and Development (R&D) expenses decreased 27% in Q2 2024, and Selling, General, and Administrative (SG&A) expenses decreased 1%, largely due to workforce reductions implemented in 2023.
- Non-Cash Gains: "Other income (expense), net" included a significant non-cash gain of $3.0 million in Q2 2024 (and $7.5 million YTD) resulting from the remeasurement of warrant liabilities issued to Tempus AI, Inc.
- Restructuring: No restructuring charges were recorded in Q2 2024, compared to $152,000 in Q2 2023. The company completed workforce reductions and the dissolution of its China operations in prior periods.
Guidance, Outlook, and Risks
- Commercialization: The company has commenced commercialization of its NeXT Personal Dx test with Tempus AI, Inc., leveraging Tempus's sales force to reach the clinical diagnostics market.
- Customer Concentration: Revenue remains highly concentrated. Natera, Inc. accounted for 35% of Q2 2024 revenue, and Moderna, Inc. accounted for 26%. The company expects its commercial relationship with Natera to wind down by the end of 2024 as Natera brings services in-house.
- Liquidity: Management believes current cash, cash equivalents, and short-term investments ($87.0 million) are sufficient to fund operations for at least the next 12 months. The company maintains an At-The-Market (ATM) facility with $47.1 million remaining available for issuance.
- Risks: Key risks include the potential loss of major customers (Natera, VA MVP), regulatory challenges regarding FDA enforcement of Laboratory Developed Tests (LDTs), and the need for additional capital if revenue growth does not offset operating expenses.
Investor Verification Checklist
- Natera Contract Expiration: Verify the timeline and financial impact of the expected wind-down of the Natera relationship by the end of 2024.
- Tempus Commercialization: Monitor the progress of the NeXT Personal Dx commercialization with Tempus and the associated revenue recognition from the $12 million market development fees.
- VA MVP Renewals: Assess the status of future task orders from the VA Million Veteran Program, given the significant revenue decline in this segment.
- Regulatory Landscape: Review the impact of the FDA's final rule on LDTs and the company's strategy for potential premarket approvals.
- Warrant Liability Volatility: Understand how fluctuations in the company's stock price impact the fair value of the Tempus warrants and the resulting non-cash gains/losses reported in "Other income (expense), net."